107 related articles for article (PubMed ID: 1388633)
1. Rational design of immunotoxins: current progress and future prospects.
Wawrzynczak EJ
Anticancer Drug Des; 1992 Oct; 7(5):427-41. PubMed ID: 1388633
[TBL] [Abstract][Full Text] [Related]
2. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
3. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Lambert JM; Goldmacher VS; Collinson AR; Nadler LM; Blättler WA
Cancer Res; 1991 Dec; 51(23 Pt 1):6236-42. PubMed ID: 1718599
[TBL] [Abstract][Full Text] [Related]
4. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
Ojima I
Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
[TBL] [Abstract][Full Text] [Related]
5. Immunotoxin therapy of cancer.
Frankel AE
Oncology (Williston Park); 1993 May; 7(5):69-78; discussion 79-80, 83-6. PubMed ID: 8512787
[TBL] [Abstract][Full Text] [Related]
6. Immunotoxins and cytokine toxin fusion proteins.
Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR
Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283
[TBL] [Abstract][Full Text] [Related]
7. Immunotoxins: current use and future prospects in bone marrow transplantation and cancer treatment.
Neville DM
Crit Rev Ther Drug Carrier Syst; 1986; 2(4):329-52. PubMed ID: 3549005
[TBL] [Abstract][Full Text] [Related]
8. Designing effective hybrid toxins.
Katzenellenbogen JA
Chem Biol; 2005 Jul; 12(7):719-21. PubMed ID: 16039518
[TBL] [Abstract][Full Text] [Related]
9. Novel genetic immunotoxins and intracellular antibodies for cancer therapy.
Chen SY; Marasco WA
Semin Oncol; 1996 Feb; 23(1):148-53. PubMed ID: 8607024
[TBL] [Abstract][Full Text] [Related]
10. Recent progress in biomolecular engineering.
Ryu DD; Nam DH
Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic use of immunotoxins.
Cobb PW; LeMaistre CF
Semin Hematol; 1992 Jul; 29(3 Suppl 2):6-13. PubMed ID: 1509295
[TBL] [Abstract][Full Text] [Related]
12. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
Pincus SH; Cole RL; Hersh EM; Lake D; Masuho Y; Durda PJ; McClure J
J Immunol; 1991 Jun; 146(12):4315-24. PubMed ID: 1710247
[TBL] [Abstract][Full Text] [Related]
13. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
15. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma.
Vallera DA; Todhunter DA; Kuroki DW; Shu Y; Sicheneder A; Chen H
Clin Cancer Res; 2005 May; 11(10):3879-88. PubMed ID: 15897589
[TBL] [Abstract][Full Text] [Related]
16. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
[TBL] [Abstract][Full Text] [Related]
17. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
18. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
Bera TK; Pastan I
Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
[TBL] [Abstract][Full Text] [Related]
19. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
